MA46955A - Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique - Google Patents

Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique

Info

Publication number
MA46955A
MA46955A MA046955A MA46955A MA46955A MA 46955 A MA46955 A MA 46955A MA 046955 A MA046955 A MA 046955A MA 46955 A MA46955 A MA 46955A MA 46955 A MA46955 A MA 46955A
Authority
MA
Morocco
Prior art keywords
peptidique
glp1
trigonal
gip
glucagon
Prior art date
Application number
MA046955A
Other languages
English (en)
Inventor
Martin Bossart
Andreas Evers
Torsten Haack
Dieter Kadereit
Katrin Lorenz
Martin Lorenz
Stefania Pfeiffer-Marek
Michael Wagner
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA46955A publication Critical patent/MA46955A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046955A 2016-12-02 2017-12-01 Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique MA46955A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306604 2016-12-02

Publications (1)

Publication Number Publication Date
MA46955A true MA46955A (fr) 2021-05-19

Family

ID=57542935

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046955A MA46955A (fr) 2016-12-02 2017-12-01 Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique

Country Status (23)

Country Link
US (1) US10538567B2 (fr)
EP (1) EP3548508B1 (fr)
JP (1) JP7100033B2 (fr)
KR (1) KR102576872B1 (fr)
CN (1) CN110023329B (fr)
AR (1) AR110300A1 (fr)
AU (1) AU2017367173B2 (fr)
BR (1) BR112019011228A2 (fr)
CA (1) CA3045377A1 (fr)
CL (1) CL2019001465A1 (fr)
CO (1) CO2019006917A2 (fr)
CR (1) CR20190313A (fr)
DO (1) DOP2019000068A (fr)
EA (1) EA201991345A1 (fr)
EC (1) ECSP19046893A (fr)
IL (1) IL266984A (fr)
MA (1) MA46955A (fr)
MX (1) MX2019006429A (fr)
PE (1) PE20191143A1 (fr)
PH (1) PH12019501216A1 (fr)
TW (1) TW201833132A (fr)
UY (1) UY37506A (fr)
WO (1) WO2018100134A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CA3096495A1 (fr) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Synthese de lixisenatide comprenant une etape de coiffage
AU2019250359A1 (en) 2018-04-10 2020-11-26 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
US20230000950A1 (en) * 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
BR112022025623A2 (pt) 2020-08-07 2023-03-07 Boehringer Ingelheim Int Agonistas solúveis de receptores de npy2
MX2023001601A (es) * 2020-08-14 2023-03-07 Hanmi Pharmaceutical Co Ltd Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip.
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用
AU2021399904A1 (en) * 2020-12-16 2023-06-08 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
CA3223121A1 (fr) * 2021-06-25 2022-12-29 Eli Lilly And Company Methodes de traitement de l'apnee obstructive du sommeil
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
TW202404997A (zh) * 2022-05-27 2024-02-01 韓商Ｄ＆Ｄ製藥科技股份有限公司 肽組合物及其使用方法
WO2024067662A1 (fr) * 2022-09-28 2024-04-04 广东东阳光药业股份有限公司 Agoniste du récepteur triple glp-1/gcg/gip et son utilisation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2376314C2 (ru) 2002-10-02 2009-12-20 Зилэнд Фарма А/С Стабилизированные соединения эксендина-4
US20080019911A1 (en) * 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
WO2010148089A1 (fr) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Composés de glucagon actifs sur le récepteur gip
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
BR112014031671A2 (pt) 2012-06-21 2018-08-07 Hoffmann La Roche análogos de glucagon exibindo atividade de receptor gip
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR20150096433A (ko) 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
WO2015086732A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4
EP3080155A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物

Also Published As

Publication number Publication date
MX2019006429A (es) 2019-08-21
TW201833132A (zh) 2018-09-16
EP3548508A1 (fr) 2019-10-09
PH12019501216A1 (en) 2019-08-19
CN110023329A (zh) 2019-07-16
CN110023329B (zh) 2024-05-03
EA201991345A1 (ru) 2019-11-29
BR112019011228A2 (pt) 2019-10-15
AU2017367173A1 (en) 2019-07-18
US10538567B2 (en) 2020-01-21
KR20190085141A (ko) 2019-07-17
PE20191143A1 (es) 2019-09-02
JP7100033B2 (ja) 2022-07-12
ECSP19046893A (es) 2019-07-31
CL2019001465A1 (es) 2019-10-18
DOP2019000068A (es) 2019-05-31
US20180155406A1 (en) 2018-06-07
CA3045377A1 (fr) 2018-06-07
IL266984A (en) 2019-07-31
CO2019006917A2 (es) 2019-07-10
AU2017367173B2 (en) 2022-03-24
AR110300A1 (es) 2019-03-13
KR102576872B1 (ko) 2023-09-12
WO2018100134A1 (fr) 2018-06-07
EP3548508B1 (fr) 2021-10-27
JP2019536796A (ja) 2019-12-19
CR20190313A (es) 2019-09-11
UY37506A (es) 2018-06-29

Similar Documents

Publication Publication Date Title
MA46955A (fr) Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique
MA46452A (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA51530A (fr) Composés cycliques fondus
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA46091A (fr) Composés biaryles utiles en tant qu'immunomodulateurs
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA44233A (fr) Nouveaux composés
MA52489A (fr) Nouveaux composés
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA52754A (fr) Composés hétérocycliques tricycliques en tant qu'activateurs de sting